Ultragenyx Pharmaceutical (RARE) Liabilities and Shareholders Equity (2013 - 2026)

Ultragenyx Pharmaceutical (RARE) has 14 years of Liabilities and Shareholders Equity data on file, last reported at $1.3 billion in Q1 2026.

• On a quarterly basis, Liabilities and Shareholders Equity fell 1.21% year-over-year to $1.3 billion in Q1 2026; TTM through Mar 2026 was $5.3 billion, a 10.83% decrease from a year earlier, with the FY2025 full-year figure at $1.5 billion, up 1.93% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $1.3 billion, down from $1.5 billion in the prior quarter.
• Over the last five years, Liabilities and Shareholders Equity for RARE reached as high as $1.6 billion in Q3 2022 and fell as low as $1.2 billion in Q3 2025.
• Historically, Liabilities and Shareholders Equity has averaged $1.4 billion across 5 years, with a median of $1.4 billion in 2023.
• Across the five-year window, Liabilities and Shareholders Equity decreased 23.5% in 2023 and grew 24.25% in 2024, its largest moves.
• Year by year, Liabilities and Shareholders Equity stood at $1.5 billion in 2022, then slipped by 3.52% to $1.5 billion in 2023, then rose by 0.8% to $1.5 billion in 2024, then climbed by 1.93% to $1.5 billion in 2025, then retreated by 15.4% to $1.3 billion in 2026.
• Per Business Quant data, the three most recent Liabilities and Shareholders Equity figures were $1.3 billion in Q1 2026, $1.5 billion in Q4 2025, and $1.2 billion in Q3 2025.